Profound vs Eli Lilly
Side-by-side comparison of AI visibility scores, market position, and capabilities
FDA-cleared AI breast cancer detection suite by iCAD (acquired by RadNet 2025). ProFound AI reads 40M+ mammograms globally with 23% improved detection rate.
About
Profound AI is the medical imaging AI brand developed by iCAD, a pioneer in cancer detection technology. iCAD's ProFound AI platform applies deep learning to mammography analysis, providing radiologists with AI-powered decision support that identifies suspicious lesions, calculates cancer risk scores, and prioritizes reading worklists based on AI-assessed urgency. The system is designed to function as a second reader — augmenting rather than replacing radiologist judgment — by flagging findings that warrant closer attention and reducing the cognitive load on radiologists reviewing high volumes of routine screening mammograms.\n\nProFound AI has achieved FDA clearance as a medical device for breast cancer detection, enabling its use in clinical radiology workflows across US health systems. The platform processes mammograms in real time, integrating with existing PACS and radiology information systems so it can be deployed without disrupting established workflow. Its clinical validation studies have demonstrated a 23% improvement in cancer detection rate compared to unassisted reads, while simultaneously reducing false positives — a combination that is clinically meaningful and commercially compelling for radiology practices seeking to improve outcomes without adding radiologist time.\n\nProFound AI reads over 40 million mammograms globally, making it one of the most widely deployed FDA-cleared AI systems in radiology. iCAD was acquired by RadNet in 2025, integrating ProFound into one of the largest radiology network operators in the United States. This acquisition significantly expands ProFound's deployment footprint, as RadNet operates hundreds of imaging centers across the US and has the scale to make AI-assisted mammography a standard-of-care offering. The combination of FDA clearance, proven clinical performance, massive global deployment, and integration into a major radiology network positions ProFound AI as a market-defining product in cancer detection AI.
Indianapolis global pharma (NYSE: LLY) at $45B 2024 revenue (+32%); first healthcare company to $1T market cap (Nov 2024) with Mounjaro/Zepbound tirzepatide (37% revenue) and oral GLP-1 orforglipron Phase 3 competing with Novo Nordisk.
About
Eli Lilly and Company is an Indianapolis, Indiana-based global pharmaceutical company — publicly traded on the New York Stock Exchange (NYSE: LLY) as an S&P 500 Dow Jones Industrial Average component — that in November 2024 became the world's most valuable pharmaceutical company with a historic $1 trillion market capitalization, the first healthcare company ever to reach this milestone. In fiscal year 2024, Lilly achieved approximately $45 billion in revenue, representing 32% growth from 2023, driven by blockbuster GLP-1 medications tirzepatide (Mounjaro for type 2 diabetes and Zepbound for obesity and obstructive sleep apnea), which together accounted for 37% of 2024 revenues. Other key products include Trulicity (dulaglutide, 12% of revenue), Humalog (insulin lispro, 5%), and Kisunla (donanemab), the first new Alzheimer's therapy approved for early symptomatic disease in 2024. An oral GLP-1 pill (orforglipron) is in Phase 3 clinical trials. CEO David Ricks has led the company since 2017. Founded in 1876 by Colonel Eli Lilly in Indianapolis, the company pioneered mass production of Jonas Salk's polio vaccine in 1955 and was among the first to produce human insulin using recombinant DNA technology.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.